Sinphar Pharmaceutical Co. Ltd.
1734
Rank in Stocks
#16759
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the... Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
Share Price
$0.86811624
Last synced: 2026-11-19
Market Cap
$185.40M
Change (1 day)
-1.78%
Change (1 year)
-5.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sinphar Pharmaceutical Co. Ltd. (1734)
Category
Healthcare
Operating Margin for Sinphar Pharmaceutical Co. Ltd. (1734)
Operating Margin as of November 2026 TTM: 11.48%
According to Sinphar Pharmaceutical Co. Ltd.'s latest financial reports, its current operating margin (TTM) is 11.48%. At the end of 2025 the company had an operating margin of 12.36%.
Operating Margin history for Sinphar Pharmaceutical Co. Ltd. from 2004 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 11.48% | -7.12% |
| 2025 | 12.36% | 32.48% |
| 2024 | 9.33% | -3.32% |
| 2023 | 9.65% | 39.45% |
| 2022 | 6.92% | -193.39% |
| 2021 | -7.41% | 44.73% |
| 2020 | -5.12% | -15.93% |
| 2019 | -6.09% | 13.20% |
| 2018 | -5.38% | 82.37% |
| 2017 | -2.95% | -55.71% |
| 2016 | -6.66% | 13.65% |
| 2015 | -5.86% | -207.33% |
| 2014 | 5.46% | -13.33% |
| 2013 | 6.30% | 4.13% |
| 2012 | 6.05% | 77.94% |
| 2011 | 3.40% | -36.33% |
| 2010 | 5.34% | -28.23% |
| 2009 | 7.44% | 113.79% |
| 2008 | 3.48% | -36.96% |
| 2007 | 5.52% | 57.26% |
| 2006 | 3.51% | -57.25% |
| 2005 | 8.21% | -20.60% |
| 2004 | 10.34% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 59.80% | -94.79% |
US
|
|
| 31.60% | -97.25% |
SE
|
|
| 30.13% | -97.38% |
FR
|
|
| 29.76% | -97.41% |
HK
|
|
| 31.11% | -97.29% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sinphar Pharmaceutical Co. Ltd.'s operating margin
What is Sinphar Pharmaceutical Co. Ltd.'s operating margin?
Sinphar Pharmaceutical Co. Ltd.'s operating margin is 11.48%, as of Nov 2026.
What was Sinphar Pharmaceutical Co. Ltd.'s operating margin in 2025?
In 2025, Sinphar Pharmaceutical Co. Ltd.'s operating margin was 12.36%, compared with 9.33% in 2024.
How has Sinphar Pharmaceutical Co. Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Sinphar Pharmaceutical Co. Ltd.'s operating margin was highest in 2025 (12.36%) and lowest in 2021 (-7.41%).
How does Sinphar Pharmaceutical Co. Ltd.'s operating margin compare with similar companies?
Sinphar Pharmaceutical Co. Ltd.'s operating margin (11.48%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 59.80%.